Onco-Summaries: Daily Oncology Updates at a Glance

21/03/2026

---

• Dizal's Phase 3 WU-KONG28 trial of ZEGFROVY met its PFS endpoint as a first-line treatment of EGFRexon20ins NSCLC

---

Dizal's Phase 3 WU-KONG28 trial of ZEGFROVY met its PFS endpoint as a first-line treatment of EGFRexon20ins NSCLC (Ref)

The multinational Phase 3 WU-KONG28 trial evaluating Dizal's ZEGFROVY® (sunvozertinib) monotherapy as first-line treatment in NSCLC with EGFR exon20ins met its primary endpoint of PFS.

• The WU-KONG28 study evaluated ZEGFROVY versus platinum-based chemotherapy as first-line treatment in advanced NSCLC patients with EGFR exon20ins

• The study enrolled patients across 16 countries and regions in Asia, Europe, North America and South America

• Topline results demonstrated that ZEGFROVY significantly improved PFS vs platinum-based doublet chemotherapy, with meaningful clinical benefit

• Detailed data from the primary analysis will be submitted for presentation at an upcoming international scientific congress

Return to Top